ORIC Pharmaceuticals, Inc.
$7.84
+2.9%ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -5.3).
Valuation inputs: P/E -5.3, earnings yield N/A, momentum +2.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -33.7%, ROIC -36.3%).
Profitability stack: net margin 0.0%, ROE -33.7%, ROIC -36.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +6.5%, momentum +2.9%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
ORIC Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
ORIC Pharmaceuticals, Inc. Fair Value Envelope
No Revenue Data
ORIC has not reported any revenue values in the available annual periods.
ORIC Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
ORIC has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
ORIC has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
ORIC has not reported any net profit margin values in the available annual periods.
ORIC Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
ORIC Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
ORIC Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that ORIC stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 20.40, with estimates ranging from a low of 15.00 to a high of 25.00.
The consensus 1-year price target stands at 20.40, with estimates ranging from a low of 15.00 to a high of 25.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Mixed analyst views. Wide target range suggests differing opinions on key value drivers, growth prospects, or risk factors.
Analyst Conviction
Neutral sentiment. Fair value pricing with moderate agreement suggests wait-and-see approach or catalyst-driven opportunity.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
ORIC Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.29M worth of ORIC shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
110.0K
1.24M
-1.2M
-$1.24M
6-9 Months
0
0.00
11.0K
47.96K
-48K
-$48K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Piscitelli Dominic
Officer: Chief Financial Officer
$848K
Chacko Jacob
Director, Officer: President And Ceo
$302K
Multani Pratik S
Officer: Chief Medical Officer
$97K
Heyman Richard A.
Director
$38K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.29M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
4 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
ORIC has not reported any dividend yield values in the available annual periods.
oric Dividend History
Learning Layer
Related Guides
Build conviction on ORIC by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.